RSV Circulation and Extending the Availability of RSV Monoclonal Antibody Product Through April
Posted on April 14, 2026
Notice From State of Maine Department of Health and Human Services
In light of the extended respiratory syncytial virus (RSV) season and anticipated continued activity, this health advisory provides clinicians with updated recommendations for RSV vaccination for infants, pregnant women, and eligible adults who have not previously received RSV vaccination.
The Maine CDC is recommending clinicians maintain high index of suspicion for RSV in patients presenting with clinically compatible illness. Maine health care facilities are advised to continue to make RSV monoclonal antibody products available to patients and eligible infants through April 30. This represents an extension beyond the typical end date of March 30, reflecting the prolonged circulation of RSV this year.
Respiratory Syncytial Virus (RSV) activity in Maine is peaking later and lasting longer than in recent years. RSV is the leading cause of infant hospitalization in the U.S. For updated information on RSV circulation, see the Maine CDC Respiratory Virus Dashboard at https://www.maine.gov/dhhs/mecdc/data-reports/diseases/infectious-disease/respiratory-dashboard.